These include ALK fusions in inflammatory myofibroblastic tumors, COLIA1-PDGFB fusions in dermatofibrosarcoma protuberans and INI1/SMARCB1 mutations/deletions in epithelioid sarcoma. This evidence concerns the gene ALK and dermatofibrosarcoma protuberans.